Name: HALOZYME THERAPEUTICS INC (HALO) Stock
Brand: HALOZYME THERAPEUTICS INC
Rating: 7.5 (3 reviews)

HALO Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Embodies Affordable Growth with Strong Metrics

5 days ago - By: Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Technical and Fundamental Momentum

10 hours ago - By: Halozyme Therapeutics, Inc.

Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery

a day ago - By: The Motley Fool - Mentions: RKLB MELI SPSC WING ...

Why I Keep Buying These 10 Incredible Growth Stocks

6 days ago - By: Zacks Investment Research

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

7 days ago - By: Investor's Business Daily - Mentions: GMAB

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead?

7 days ago - By: Zacks Investment Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

8 days ago - By: Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Growth and Technical Breakout Potential

11 days ago - By: Halozyme Therapeutics, Inc.

FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma

12 days ago - By: Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

13 days ago - By: The Motley Fool - Mentions: AVGO MSFT

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

13 days ago - By: Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032

14 days ago - By: Zacks Investment Research - Mentions: JNJ ARGX

Halozyme Beats on Q3 Earnings & Revenues, Raises 2025 View

15 days ago - By: Zacks Investment Research

Halozyme Therapeutics (HALO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

15 days ago - By: Zacks Investment Research - Mentions: BHST

Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates

15 days ago - By: Halozyme Therapeutics, Inc.

HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS

18 days ago - By: Benzinga

Insights into Halozyme Therapeutics's Upcoming Earnings

19 days ago - By: Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Fits a Proven Growth Investing Method

a month ago - By: Zacks Investment Research - Mentions: JNJ

Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?

a month ago - By: Halozyme Therapeutics, Inc.

Halozyme to Report Third Quarter 2025 Financial and Operating Results

a month ago - By: Zacks Investment Research

Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?

a month ago - By: Benzinga

The Analyst Verdict: Halozyme Therapeutics In The Eyes Of 10 Experts

2 months ago - By: Zacks Investment Research

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

2 months ago - By: Halozyme Therapeutics, Inc.

Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s

2 months ago - By: Zacks Investment Research - Mentions: ABBV ANIP ARGX

AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease

2 months ago - By: Investor's Business Daily - Mentions: UTHR AUPH ARGX

HALOZYME THERAPEUTICS INC (HALO) Stock News